Table 1.
Baseline characteristics of patients treated with NAC (N = 247)
| Characteristics | Absolute lymphocyte count ≤1.49 × 109/L (n = 150) | Absolute lymphocyte count >1.49 × 109/L (n = 97) | P‐value |
|---|---|---|---|
| Age, median (range), y | 57 (31‐80) | 60 (27‐79) | 0.175 |
| ASA score, n (%) | |||
| 1 | 28 (18.7%) | 13 (13.4%) | 0.500 |
| 2 | 90 (60.0%) | 57 (58.8%) | |
| 3 | 30 (20.0%) | 26 (26.8%) | |
| 4 | 2 (1.3%) | 1 (1.0%) | |
| CA‐125 level, median (range), U/mL | 1781.5 (44.3‐20685.7) | 1509.0 (66.7‐17911.3) | 0.161 |
| Hemoglobin level, median (range), g/L | 12.1 g/L (8.3‐16.3) | 12.5 g/L (9.4‐15.7) | 0.015 |
| Absolute lymphocyte count, median (range), cells/L | 1.09 × 109/L (0.31‐1.47) | 1.85 × 109/L (1.50‐3.10) | <0.001 |
| Absolute neutrophil count, median (range), cells/L | 5.40 × 109/L (0.66‐14.02) | 5.15 × 109/L (1.49‐36.52) | 0.316 |
| FIGO stage, n (%) | |||
| III | 72 (48.0%) | 40 (41.2%) | 0.360 |
| IV | 78 (52.0%) | 57 (58.8%) | |
| Histologic type, n (%) | |||
| HGSC | 137 (91.3%) | 89 (91.8%) | 0.986 |
| Endometrioid | 2 (1.3%) | 1 (1.0%) | |
| Mucinous | 2 (1.3%) | 2 (2.1%) | |
| Others | 9 (6.0%) | 5 (5.2%) | |
| Grading | |||
| 1 | 5 (3.3%) | 3 (3.1%) | 0.121 |
| 2 | 23 (15.3%) | 11 (11.3%) | |
| 3 | 100 (66.7%) | 77 (79.4%) | |
| Not available | 22 (14.7%) | 6 (6.2%) | |
| Residual disease, n (%) | |||
| No | 53 (35.3%) | 45 (46.4%) | 0.212 |
| Any residual | 82 (54.7%) | 45 (46.4%) | |
| Not available | 15 (10.0%) | 7 (7.2%) | |
| Chemotherapy regimen, n (%) | |||
| Paclitaxel + carboplatin | 113 (75.3%) | 81 (83.5%) | 0.286 |
| Docetaxel + carboplatin | 34 (22.7%) | 14 (14.4%) | |
| Paclitaxel + carboplatin + bevacizumab | 3 (2.0%) | 2 (2.1%) | |
| Cycles of total chemotherapy, median (range) | 8 (4‐12) | 8 (3‐12) | 0.225 |
ASA, American Society of Anesthesiologists; CA‐125, cancer antigen 125; FIGO, International Federation of Gynecology and Obstetrics; HGSC, high‐grade serous carcinoma; NAC, neoadjuvant chemotherapy.